【摘要】 目的:观察放射性125Ⅰ粒子源治疗中晚期肺癌的疗效。方法:首先利用实体肿瘤等效材料,采用热释光剂量学方法,模拟实测了125I粒籽源植入瘤内后,瘤内外剂量分布,并对其剂量影响因素进行了详细研究;临床共对38例中晚期肺癌患者进行125I粒子种植,均采用电视胸腔镜辅助小切口下实施手术,进行临床观察。结果:根据实验研究结果确定125I粒子间距为1cm时能够达到治疗量(处方剂量145Gy);本组38例患者术后恢复顺利,手术后未发生出血、气胸、肺感染、肺不张等并发症。临床观察6个月,临床分析结果显示总缓解率为63.16%,咳嗽、气短、纳差、胸疼症状明显减轻,生活质量均有不同程度的改善(P<0.05)。结论:放射性125Ⅰ粒子源对于不能手术切除的中晚期肺癌是一种安全有效的治疗方法。更多还原

【Abstract】 Objective: To investigate the clinical efficacy of radioactive iodine-125 interstitial brachytherapy for treatment of middle to late stage lung cancer. Methods: The dose distribution of iodine-125 seeds was assessed by thermoluminescence dosimetry method (TLD) and dose calculation formula. The radial dose of iodine-125 seeds was compared using measured and calculated results. Thirty-eight patients with unresectable middle to late stage lung cancer were treated with interstitial radiation of iodine-125 seed implants. The iodine-125 seeds were implanted into the carcinoma by video adapter thoracoscope(VATS). Results: The experimental results indicated that the effective interstitial space of the seeds was 1cm. After 6 months, the total response rate(CR+PR) was 63.16%, and the symptoms of cough, shortness of breath, decreased appetite and chest pain were obviously reduced after surgery. There was no massive bleeding, pneumothorax, pneumonia or atelectasis after surgery. Conclusion: Radioactive iodine-125 seed implants are safe and effective and might be helpful in the treatment of unresectable middle to late stage lung cancer.更多还原